Product name
Immunomodulating Protein for the Treatment of Autoimmune DiseasesSummary
IPSE/alpha-1 has been identified as a molecule with highly potent immunomodulating propertiesOrganization name
Ascenion GmbHProfile
A pathological immune response is the major cause for a number of disease states including autoimmune diseases, acute transplant rejection or allergic reactions.
Hence modulation of the immune response, e.g. the redirection of a Th1 response towards a Th2 response, has gained wide acceptance as a promising therapeutic option. New potent substances are needed, that specifically modulate the immune response without causing side-effects.
The Technology
The eggs of the parasitic trematode Schistosoma mansoni induce a pronounced Th2 response and immunoglobulin E (IgE) production both in humans and in experimental animals. In egg extracts the protein IPSE/alpha-1 has been identified as a molecule with highly potent immunomodulating properties. Cell culture experiments show that even very low concentrations of IPSE/alpha-1 lead to the release of IL-4 and IL-13 from basophilic granulocytes.
Commercial Opportunity
The proven immunomodulating properties of IPSE/alpha-1 make this protein an interesting candidate for developing a therapeutic agent. The technology is offered for licensing or for further development in a cooperation.
Patent Situation
Pending patent applications in Germany, Europe, USA and Japan.
Contact
Dr. Hinrich Habeck
Technology Scout
habeck(at)ascenion.de
About Ascenion
Ascenion is the exclusive partner of 12 life-science institutes in the Helmholtz and Leibniz Associations and of one Medical School, and coordinates technology transfer for the German National Genome Research Network. They currently market around 600 technologies, together with a varied range of research materials, e.g. antibodies, animal models and vectors.
Description File
14-00008_Technology_Offer.pdf
print this page
